

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (Withdrawn) A therapeutic agent for glioblastoma, which comprises a compound having an activity of inhibiting an AMPA receptor as the active ingredient.
2. (Withdrawn) A therapeutic agent for glioblastoma according to claim 1, wherein the compound having an activity of inhibiting an AMPA receptor is [7-(1H-imidazol-1-yl)-6-nitro-2,3-dioxo-3,4-dihydroquinoxalin-1(2H)-yl]acetic acid or a salt thereof or a hydrate thereof.
3. (Withdrawn) A therapeutic agent for glioblastoma according to claim 1, wherein the compound having an activity of inhibiting an AMPA receptor is 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)-quinoxaline or a salt thereof.
4. (Withdrawn) A therapeutic agent for glioblastoma according to claim 1, wherein the compound having an activity of inhibiting an AMPA receptor is 2-[N-(4-chlorophenyl)-N-methylamino]-4H-pyrido[3,2-e]-1,3-thiazin-4-one or a salt thereof.
5. (Withdrawn) A pharmaceutical composition for use as a therapeutic agent for glioblastoma, the pharmaceutical composition containing a therapeutically effective amount of a

compound having an activity of inhibiting an AMPA receptor and a pharmaceutically acceptable carrier.

6. (Withdrawn) A pharmaceutical composition according to claim 5, wherein the compound having an activity of inhibiting an AMPA receptor is [7-(1H-imidazol-1-yl)-6-nitro-2,3-dioxo-3,4-dihydroquinoxalin-1(2H)-yl]acetic acid or a salt thereof or a hydrate thereof.

7. (Withdrawn) A pharmaceutical composition according to claim 5, wherein the compound having an activity of inhibiting an AMPA receptor is 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)-quinoxaline or a salt thereof.

8. (Withdrawn) A pharmaceutical composition according to claim 5, wherein the compound having an activity of inhibiting an AMPA receptor is 2-[N-(4-chlorophenyl)-N-methylamino]-4H-pyrido[3,2-e]-1,3-thiazin-4-one or a salt thereof.

9. (Withdrawn) Use of a compound having an activity of inhibiting an AMPA receptor for the manufacture of a medicament for treating glioblastoma comprising a clinically effective amount of the compound.

10. (Withdrawn) Use according to claim 9, wherein the compound having an activity of inhibiting an AMPA receptor is [7-(1H-imidazol-1-yl)-6-nitro-2,3-dioxo-3,4-dihydroquinoxalin-1(2H)-yl]acetic acid or a salt thereof or a hydrate thereof.

11. (Withdrawn) Use according to claim 9, wherein the compound having an activity of inhibiting an AMPA receptor is 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)-quinoxaline or a salt thereof.

12. (Withdrawn) Use according to claim 9, wherein the compound having an activity of inhibiting an AMPA receptor is 2-[N-(4-chlorophenyl)-N-methylamino]-4H-pyrido[3,2-e]-1,3-thiazin-4-one or a salt thereof or a hydrate thereof.

13. (currently amended): A method for treating glioblastoma comprising administering a therapeutically effective amount of a compound having an activity of inhibiting an α -amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor to a patient with the disease, wherein the compound is [7-(1H-imidazol-1-yl)-6-nitro-2,3-dioxo-3,4-dihydroquinoxalin-1(2H)-yl]acetic acid or a salt thereof; 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)-quinoxaline or a salt thereof; 2-[N-(4-chlorophenyl)-N-methylamino]-4H-pyrido[3,2-e]-1,3-thiazin-4-one or a salt thereof; 1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine or a salt thereof, or 7-acetyl-5-(4-aminophenyl)-8(R)-methyl-8,9-dihydro-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine or a salt thereof.

14. (withdrawn): A method according to claim 13, wherein the compound having an activity of inhibiting an AMPA receptor is [7-(1H-imidazol-1-yl)-6-nitro-2,3-dioxo-3,4-dihydroquinoxalin-1(2H)-yl]acetic acid or a salt thereof.

15. (withdrawn) A method according to claim 13, wherein the compound having an activity of inhibiting an AMPA receptor is 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)-quinoxaline or a salt thereof.

16. (withdrawn) A method according to claim 13, wherein the compound having an activity of inhibiting an AMPA receptor is 2-[N-(4-chlorophenyl)-N-methylamino]-4H-pyrido[3,2-e]-1,3-thiazin-4-one or a salt thereof.

17. (withdrawn) A method according to claim 13, wherein the compound having an activity of inhibiting an AMPA receptor is 1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine or a salt thereof.

18. (Previously presented) A method according to claim 13, wherein the compound having an activity of inhibiting an AMPA receptor is 7-acetyl-5-(4-aminophenyl)-8(R)-methyl-8,9-dihydro-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine or a salt thereof.

19. (previously presented): A method according to claim 13, wherein the compound having an activity of inhibiting an AMPA receptor is selected from the group consisting of 1-(piperidin-1-yl)-1-(quinoxalin-6-yl)methanone, 4,5-dihydro-1-methyl-4-oxo-7-(trifluoromethyl)-imidazo[1,2-a]quinoxaline-2-carboxylic acid, N-((1-(1-carboxymethyl-5,6,7,8-tetrahydro-benzo [f] quinoxaline-2,3-(1H,4H)-dion-9-yl)-pyrrol-3-yl)methyl-N'-(4-carboxyphenyl)-urea, 1-(2-acetamidoethyl)-2,5-dimethylpyrrole-3-carboxaldehyde, 6-(4-chlorophenyl)-6,7-dihydroimidazo[1,2-a]pyrazin-8(5H)-one, N,N-dimethyl-N-[2-[2-(3-phenyl-

1,2,4-oxadiazol-5-yl)phenoxy]ethyl]amine, amino-3-hydroxy-5-methyl-4-isoxazolepropionate, 6-[2-(1H-tetrazol-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid, (3S,4aR,6R,8aR)-decahydro-6-[2-(1H-tetrazol-5-yl)ethyl]-3-isoquinolinecarboxylic acid, 2-amino-3-[2-[3-(1H-tetrazol-5-yl)phenoxy]phenyl]propionic acid, (-)(3S,4aR,6R,8aR)-6-[2-(1(2) H-tetrazole-5-yl)ethyl] 1,2,3,4,4a,5,6,7,8, 8a-decahydroisoquinoline-3-carboxylic acid monohydrate, (3S,4aR,6S,8aR)-6-(1H-tetrazol-5-ylmethoxymethyl)perhydroisoquinoline-3-carboxylic acid, N-[2-(4'-cyanobiphenyl-4-yl)propyl]propane-2-sulfonamide, 3-methylsulfonylamino-6,7-dinitro-2(1H)-quinoxalinone, 6-(aminophenyl)-8-chloro-2-methyl-1H-imidazo[1,2-c][2,3]benzodiazepine, 1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine, 5-(4-aminophenyl)-8,9-dihydro-N,8-dimethyl-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine-7-carboxamide, 7-acetyl-5-(4-aminophenyl)-8(R)-methyl-8,9-dihydro-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine, 2,3-O-isopropylidene-4,5-O-sulfonyl-β-D-fructopyranose 1-O-sulfamate, 6-trifluoromethyl-3-oxo-7-[4-(4-carboxyphenylaminocarbonyloxymethyl)imidazol-1]-3,4-dihydroquinoxaline-2-carboxylic acid, 2-[[[5-[4-[(dimethylamino)sulfonyl]phenyl]-1,2,6,7,8,9-hexahydro-8-methyl-2-oxo-3H-pyrrolo[3,2-h]isoquinolin-3-ylidene]amino]oxy]-3-hydroxy-butanoic acid, 3-(hydroxyimino)-N,N-dimethyl-2-oxo-2,3,6,7,8,9-hexahydro-1H-benzo [g] indole-5-sulfonamide, 9-methyl-6-nitro-1,4,7,8,9,10-hexahydropyrido [3,4-f] quinoxaline-2,3-dione, 7-nitro-5-(phosphonomethylamino)methyl-1,3-dihydro-quinoxalin-2,3-dione, 2-hydroxy-4-(2-nitroethyl)benzaldehyde, 2-carboxy-1-methyl-7-trifluoromethylimidazo[1,2-a]quinoxalin-4(5H)-one, 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)-quinoxaline, 7-chloro-3-nitro-1,2,3,4-tetrahydroquinolin-2-one, N-methyl-N-(6-methyl-7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl)glycine, 6-methyl-7-nitro-5-(1-piperidylmethyl)quinoxaline-

2,3(1H,4H)-dione, 6-fluoro-3-(2-chlorophenyl)-2-[(6-diethylaminomethyl)pyridin-2-yl] ethenyl-quinazolin-4-one, 1,2,3,6,7,8-hexahydro-3-(hydroxyimino)-N,N,7-trimethyl-2-oxo-benzo[2,1-b:3,4-c']dipyrrole-5-sulfonamide, 9-methyl-6-nitro-1,4,7,8,9,10-hexahydropyrido[3,4-f]quinoxaline-2,3-dione, 1-(4-aminophenyl)-7,8-(methylenedioxy)-3,5-dihydro-4H-2,3-benzodiazepin-4-one, 6-(4-pyridinyl)-1H-1,2,3-triazolo[4,5-a]pyrimidin-4(5H)-one, 7-morpholino-2,3-dioxo-6-trifluoromethyl-1,2,3,4-tetrahydro-quinoxaline-1-methylphosphonic acid, 7-acetyl-5-(4-aminophenyl)-8,9-dihydro-8-methyl-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine-8-carbonitrile, [+/-]-1-[4-aminophenyl]-3-[N-cyclopropyl-carbamoyl]-4-methyl-7,8-methylenedioxy-5H-3,4-dihydro-2,3-benzodiazepine, 7-nitro-2,3-dioxo-N- [2-(1-piperidinyl) ethyl] -1,2,3,4-tetrahydroquinoxaline- 6-sulfonamide, 6,7-dichloro-2(1H)-oxoquinoline-3-phosphonic acid, 7-chloro-6-sulfamoyl-2-(1H)-quinoleinone-3-phosphonic acid, 6-nitro-3-oxo-7-(4-oxo-1,4-dihydropyridin-1-yl)-1,2,3,4-tetrahydroquinoxalin-2-ylidenecyanamide, 1-methyl-6-methoxy-4-(4-aminophenyl)-2-(3-propylamino)carbonyl-1, 2-dihydrophthalazine, 1-methyl-6,7-dioxamethyl-4-(4-aminophenyl)-2-(3-propylamino)carbonyl-1, 2- dihydrophthalazine, 4-(aminophenyl)-1-methyl-6,7-(methylenedioxy)-N-butyl-1,2-dihydrophthalazine-2-carboxamide, 6, 7-dioxamethyl-4-(4-aminophenyl)-2- (3-propylamino)carbonyl-1, 2- dihydrophthalazine, 4-(4-aminophenyl)-N-ethyl-1-methyl-6-(methylsulfanyl)-1,2-dihydrophthalazine-2-carboxamide, 4-(3-acetyl-7-methoxy-4-methyl-4,5-dihydro-3H-2,3-benzodiazepin-1-yl)phenylamine, 1,4-dihydro-6-(1H-imidazol-1-yl)-7-nitro-2,3-quinoxalinedione, 7-chloro-4-oxo-8-(4H-1,2,4-triazol-4-yl)-4,5-dihydro- [1,2,4] triazolo [1,5-a] quinoxaline-2-carboxylic acid, 3- [5- [2- [[(3, 5-dichloro-4-hydroxy) phenylcarbonyl] amino] carboxyethyl] -2-carboxypyrrolidin-2yl]-serine, [7-(1H-imidazol-1-yl)-6-nitro-2,3-dioxo-3,4-

dihydroquinoxalin-1(2H)-yl]acetic acid, 2-[N-(4-chlorophenyl)-N-methylamino]-4H-pyrido[3,2-e]-1,3-thiazin-4-one, and salts thereof.